Brighton TA, Eikelboom JW, Mann K, Biostat M, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Low-dose, Simes J

Language: Spanish
References: 10
Page: 89-91
PDF size: 184.41 Kb.

Text Extraction

No abstract.

REFERENCES

1. Patrono C, Rocca B. Aspirin, 110 years later. J Thromb Haemost 2009; 7 Suppl 1: 258-261.

2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.

3. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e278S-325S.

4. Liew NC, Chang YH, Choi G, Chu PH, Gao X, Gibbs H, et al. Asian venous thromboembolism guidelines: prevention of venous thromboembolism. Int Angiol 2012; 31: 501-516.

5. Becker RC. Aspirin and the prevention of venous thromboembolism. N Engl J Med 2012; 366: 2028- 2030.

6. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959-1967.

7. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367: 1979-1987.

8. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001; 85: 265-271.

9. Raju NC, Eikelboom JW. The aspirin controversy in primary prevention. Curr Opin Cardiol 2012; 27: 499- 507.

10. Patrono C. El ácido acetilsalicílico continúa siendo objeto de investigación y debate 115 años después de su síntesis. Rev Esp Cardiol 2012; [Epub ahead of print].